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Summary We report the results of the first use of a steroidal aromatase inhibitor, 4-hydroxyandrostenedione
(4-OHA, CGP 32349), in the palliation of patients with advanced, hormone resistant, prostatic cancer. Twelve
of 19 patients (63%), who had relapsed following castration and other therapies, gained significant pain relief
following weekly intramuscular injections of 4-OHA. Five patients (31%) experienced a transient 'tumour
flare', represented by an increase in bone pain soon after commencing treatment. The mechanism of action of
4-OHA in palliating patients with advanced prostatic cancer is obscure at present, but may represent an
important new treatment modality which may lead to greater insight into prostatic biology.
Prostate cancer is the third commonest cause of male cancer
deaths in the UK and 60% of patients have evidence of
metastases at the time of presentation (Chisholm, 1980).
Conventional first-line therapy for patients with advanced
prostatic cancer is aimed at the reduction of circulating
androgen levels and suppression of androgen-dependent
growth. Approximately 80% of patients treated in this way
will respond, the median duration of response being 15
months (Parker et al., 1985). All patients eventually relapse,
becoming hormone insensitive, and their treatment at this
stage is a difficult problem (Lancet, 1980) consisting mainly
of alleviation of symptoms using analgesia, steroids, pal-
liative single fraction radiotherapy and hemibody irradiation.
An alternative approach is the reduction of residual cir-
culating androgens which result from adrenal secretion, in an
attempt to produce a further hormonal response. Such
therapy includes the use of aminoglutethimide (AG). We
have previously reported our experience with AG and corti-
sone acetate with a subjective response of almost 50%
(Ponder et al., 1984).
Detailed analysis of the endocrine changes associated with
this regime showed that although there was a fall in cir-
culating androgens from administration of glucocorticoid, no
change was attributable to AG (Plowman et al., 1987;
Dowsett et al., 1988). We therefore concluded that any
clinical effect of AG was not due to androgen suppression.
The lack of specificity of AG and the need to use it in
combination with glucocorticoids make it difficult to assign a
mechanism of action with confidence. AG is an aromatase
inhibitor and it has been suggested that this could be its
mode of action in palliating patients with advanced prostate
cancer (Worgul et al., 1983). To investigate this hypothesis
further, we have evaluated a more selective aromatase
inhibitor, 4-OHA, in patients with advanced prostatic cancer
who had relapsed following castration, presenting mainly
with severe bone pain.
Patients and methods
All patients had histologically proved carcinoma of the pros-
tate with bone pain associated with metastases demonstrated
on radio-isotopic bone scintigraphy. All patients had pre-
viously been treated by bilateral orchidectomy. Most had
received palliative radiotherapy and AG/cortisone, and had
either not responded, or relapsed after initial response.
4-OHA was given by weekly intramuscular injection in a
dose of 500mg. In two patients, the dose was reduced to
250 mg fortnightly because of pain at the injection site.
Patients were assessed on entry to the trial and fortnightly
while on treatment. Subjective assessment was by evaluation
of symptoms (pain level, analgesic requirement and perfor-
mance) using the Eastern Cooperative Oncology Group
(ECOG) scale (Table I). A complete subjective response was
defined as an ECOG score of 0 on 2 consecutive occasions at
least 4 weeks apart and partial response as a reduction in
ECOG score of > 50%. No formal objective measurements
were performed in these patients although eight patients had
blood taken for oestradiol, testosterone, dihydrotestosterone
and androstenedione estimations pre and post treatment with
4-OHA.
Results
Nineteen patients were admitted to the trial. The age range
was 58 to 83 years (average 68). All patients had previously
undergone orchidectomy (13-33 months before entry: aver-
age 17) and 11 had been treated with AG and hydrocortisone
(starting 4-13 months before entry: average 7). In all cases,
AG and hydrocortisone was discontinued before entry.
ECOG scores on entry ranged from 6 to 12.
Complete subjective response was seen in 4 (21%) and
Table I The Eastern Co-operative Oncology Group (ECOG) scale for
subjective assessment
1. Pain
None
Slight/mild: little
interference with non-
strenuous activities
Quite bad: interferes with
daily activities and/or sleep
Severe: distracted by pain
much of the time
Intolerable: dominates life
3. Performance status
Fully active
Active: capable of light
work
Restricted: in bed <50%
of the time; capable of self
care
Restricted: in bed > 50%
of the time; limited self
care
Bed-ridden
2. Analgesic requirement
0 None
Non-narcotic
I occasional
regular
Narcotic
occasional
regular
2
3
4
0
2
3
4
0 Scores are added:
1 Range is from
to
0 (best)
12 (worst)
2
3
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partial response in 8 (42%), giving a total subjective response
of 63%. In 10 of these 12 patients, the ECOG score at 4
weeks was 4 or less. Average duration of response was 10
weeks. No patient remained in remission for more than 16
weeks.
Side effects were few: 5 patients (31%) had a transient
increase in bone pain following the first injection, neces-
sitating an increase in analgesia. We attributed this to a
'tumour flare', the mechanism of which remains obscure.
Most patients complained of pain at the injection site for
24-48 hours after each injection. In two cases this neces-
sitated dose reduction but no patient had to discontinue
treatment because of side effects.
In the 8 patients on whom endocrine studies were per-
formed, 5 showed a significant decrease in oestradiol levels.
There were no changes in testosterone, dihydrotestosterone
or androstenedione levels.
Discussion
Androgen deprivation has been the mainstay of treatment for
advanced prostatic cancer since the pioneering studies of
Huggins and Hodges (1941) on the effects of castration or
oestrogen administration on men with prostate cancer. The
use of anti-androgens (Scott & Schirmer, 1966) and LHRH
analogues (Ahmed et al., 1985) have also been described.
However, the role of oestrogens in prostatic biology is less
well defined (for review see Mawhinney & Neubauer, 1979).
It has been suggested that oestrogen suppression by
aromatase inhibitors may be of benefit in benign prostatic
hypertrophy (Henderson et al., 1986) although there is no
experimental evidence as yet to implicate oestrogens in the
causation or control of the malignant prostate.
Aromatase (oestrogen synthetase) is a key enzyme in the
steroidogenic pathway from cholesterol to oestrogens. It
mediates the conversion of androgens to oestrogens and is an
enzyme complex involving NADPH, cytochrome c reductase
and cytochrome p450. It is present in many tissues partic-
ularly placenta, breast, ovary, testes and adipose tissue. Its
presence in prostate in vitro has been described (Stone et al.,
1986) although it is still contentious (Smith et al., 1982).
Aromatisation is the last reaction in the production of
oestrogens and therefore blockage of this enzyme will not
cause depletion of other steroids.
Selective inhibition of aromatase may be achieved by com-
pounds which interfere with androgen aromatisation by bind-
ing to the enzyme, or by compounds, i.e. AG, which bind to
cytochrome p450 and therefore act as competitive inhibitors.
4-OHA is a potent 'suicide inhibitor' of aromatase (Brodie et
al., 1981) acting both by competition with the substrate and
inactivation of the enzyme causing irreversible inhibition.
Clinically, 4-OHA is in clinical trial use for the treatment
of post-menopausal women with advanced breast cancer
(Coombes et al., 1984).
All the patients in this study had 'end-stage' disease and
we were struck by the quality of their responses, in marked
contrast to those seen with AG/cortisone. Their feeling of
well being was remarkable, and three of the patients were
able to return to work for the duration of their remissions.
Although subjective responses in such patients are open to
criticism, the tumour 'flare' seen after the first injection sug-
gests that there is a true biological response to aromatase
inhibition. Additionally, the decrease in oestradiol levels
observed in 5 of 8 patients in which it was measured lends
support to this hypothesis.
This is the first study which describes the use of a selective
aromatase inhibitor in patients with advanced, hormone
insensitive, prostate cancer. We have recently commenced a
clinical trial using 4-OHA in patients with advanced prostate
cancer, which will include detailed objective measurements
and endocrine analysis during treatment. We have also com-
menced laboratory studies to investigate the mechanism of
action of 4-OHA in prostatic biology further.
4-OHA was supplied by Ciba-Geigy Pharmaceuticals, Horsham, West
Sussex.
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